Skip to main content
QUIT logo

QUIT · Achieve Life Sciences, Inc. · Documents

Track QUIT — free
$5.73 -0.15 (-2.47%) Play latest call Q1 2026 earnings call transcript
Market Cap
$645.90M
Shares
110.03M
Volume · Nov 20 693.7K Avg daily vol (3M) 1.37M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $54.65M 10-K filed Mar 24, 2026 Quarterly report FY2026 Q3 Net loss $12.11M 10-Q filed Nov 10, 2026 Latest results Cash reaches $201.5 million; NDA resubmission on track 8-K filed Nov 10, 2026 Earnings call Q1 2026 earnings call Held May 12, 2026
2026
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA Complete Response Letter cites cytisinicline manufacturing and labeling issues

Achieve Life Sciences received an FDA Complete Response Letter for cytisinicline citing manufacturing and labeling issues. It plans to resubmit in the fourth quarter of 2026 and anticipates potential approval by the end of the second quarter of 2027.

Net loss $12.11M Diluted EPS -$0.11
Read from the MD&A section
3 source passages
In June 2026, we received a Complete Response Letter, or CRL, from the FDA regarding our NDA for cytisinicline relating to outstanding manufacturing-related observations from a current Good Manufacturing Practice, or cGMP, inspection of a third-party manufacturing facility and to final product labeling that was not completed by the FDA’s action date. We intend to resubmit the NDA naming Adare as our finished drug product manufacturer for commercial supply in the fourth quarter of 2026 and anticipate the potential approval of cytisinicline for smoking cessation by the end of the second quarter of 2027, followed by U.S. commercial launch. Achieve is party to the Sopharma Supply Agreement with Sopharma AD, or Sopharma. Open the document at this passage
Nov 10
Current report 8-K
Cash reaches $201.5 million; NDA resubmission on track

AchieveRx reported cash, cash equivalents, and marketable securities of $201.5 million as of September 30, 2026. Cytisinicline’s NDA resubmission remains on track for the fourth quarter of 2026; third-quarter net loss was $12.1 million.

Financial results
4 source passages
Cash, cash equivalents, and marketable securities of $201.5 million as of September 30, 2026 Resubmission of the New Drug Application (NDA) remains on track for the fourth quarter of 2026 Total net loss for the three and nine months ended September 30, 2026, were $12.1 million and $97.0 million, respectively. Achieve Life Sciences, Inc., doing business as AchieveRx (AchieveRx or the Company) (Nasdaq: QUIT) Open the document at this passage
Oct 1
Current report 8-K
Director or officer change, or executive pay

Achieve Life Sciences, Inc. appointed Benjamin Halladay as Chief Financial Officer and principal financial officer effective as of October 5, 2026, while Mark Oki stepped down from the same role effective as of October 5, 2026.

Aug 14
Current report 8-K
Other events AI summary on its way
Mar 24
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $54.65M Diluted EPS -$1.25
2025
2024
Showing 1–50 of 153 documents
Key facts CIK 949858 13F (30d) 142 filings 123 filers Visit website Investor relations